• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea.

作者信息

Alvarez-Larrán Alberto, Díaz-González Alvaro, Such Esperanza, Mora Elvira, Andrade-Campos Marcio, García-Hernández Carmen, Gómez-Casares M Teresa, García-Gutiérrez Valentín, Carreño-Tarragona Gonzalo, Garrote Marta, Fernández-Ibarrondo Lierni, Cervera José, Bellosillo Beatriz, Cervantes Francisco, Hernández-Boluda Juan Carlos

机构信息

Hematology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Hematology Department, Hospital La Fe, Valencia, Spain.

出版信息

Leukemia. 2021 Feb;35(2):623-627. doi: 10.1038/s41375-020-0849-2. Epub 2020 May 5.

DOI:10.1038/s41375-020-0849-2
PMID:32372025
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7862052/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b2/7862052/752761d76f92/41375_2020_849_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b2/7862052/f25ba4b73a7c/41375_2020_849_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b2/7862052/752761d76f92/41375_2020_849_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b2/7862052/f25ba4b73a7c/41375_2020_849_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b2/7862052/752761d76f92/41375_2020_849_Fig2_HTML.jpg

相似文献

1
Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea.真性红细胞增多症患者对羟基脲产生耐药性的基因组特征分析。
Leukemia. 2021 Feb;35(2):623-627. doi: 10.1038/s41375-020-0849-2. Epub 2020 May 5.
2
Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.聚乙二醇化干扰素α-2a与羟基脲治疗真性红细胞增多症和原发性血小板增多症：细胞和分子反应的差异
Leukemia. 2018 Aug;32(8):1830-1833. doi: 10.1038/s41375-018-0080-6. Epub 2018 Feb 28.
3
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.鲁索利替尼治疗对羟基脲耐药/不耐受且无其他治疗选择的真性红细胞增多症患者的开放标签、多中心、3b 期扩展治疗方案研究的安全性和疗效结果。
Leuk Lymphoma. 2019 Dec;60(14):3493-3502. doi: 10.1080/10428194.2019.1636985. Epub 2019 Jul 30.
4
Differential expression of hydroxyurea transporters in normal and polycythemia vera hematopoietic stem and progenitor cell subpopulations.羟脲载体在正常和真性红细胞增多症造血干祖细胞亚群中的差异表达。
Exp Hematol. 2021 May;97:47-56.e5. doi: 10.1016/j.exphem.2021.02.011. Epub 2021 Mar 4.
5
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.JAK2 和 Src 激酶基因在对真性红细胞增多症和原发性血小板增多症羟脲治疗的反应中的差异表达。
Ann Hematol. 2011 Aug;90(8):939-46. doi: 10.1007/s00277-011-1179-2. Epub 2011 Feb 18.
6
Hydroxyurea-induced stomatocytes in a patient presenting with polycythemia vera.羟基脲诱发的口形红细胞见于一名真性红细胞增多症患者。
Am J Hematol. 2015 Jun;90(6):573. doi: 10.1002/ajh.23926. Epub 2015 May 10.
7
Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera.真性红细胞增多症患者诊断时的年轻与老年具有不同的基因组特征。
Leukemia. 2019 Jun;33(6):1522-1526. doi: 10.1038/s41375-018-0349-9. Epub 2019 Jan 11.
8
The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.羟基脲对原发性血小板增多症和真性红细胞增多症患者PRV-1表达的影响。
Haematologica. 2004 Oct;89(10):1264-6.
9
Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?真性红细胞增多症、鲁索替尼和羟基脲：我们现在何去何从？
Lancet Haematol. 2020 Mar;7(3):e184-e185. doi: 10.1016/S2352-3026(19)30262-5. Epub 2020 Jan 23.
10
From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.从疗效到安全性：真性红细胞增多症研究组关于羟基脲治疗真性红细胞增多症患者的报告
Semin Hematol. 1997 Jan;34(1):17-23.

引用本文的文献

1
Differences in Clinical Outcomes Between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients.羟基脲耐药和不耐受真性红细胞增多症患者的临床结局差异。
J Korean Med Sci. 2024 Jan 22;39(3):e24. doi: 10.3346/jkms.2024.39.e24.
2
Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms.长效干扰素：骨髓增殖性肿瘤的开创性疾病修饰治疗。
Korean J Intern Med. 2023 Nov;38(6):810-817. doi: 10.3904/kjim.2023.333. Epub 2023 Nov 1.
3
-negative myeloproliferative neoplasms in the era of next-generation sequencing.
下一代测序时代的阴性骨髓增殖性肿瘤
Front Genet. 2023 Sep 8;14:1241912. doi: 10.3389/fgene.2023.1241912. eCollection 2023.
4
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project.识别羟基脲起始治疗后有血栓形成风险的真性红细胞增多症患者：真性红细胞增多症-高级综合模型（PV-AIM）项目
Biomedicines. 2023 Jul 7;11(7):1925. doi: 10.3390/biomedicines11071925.
5
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.骨髓增殖性肿瘤中的克隆结构演变：从驱动突变到复杂的异质性突变和表型景观。
Leukemia. 2023 May;37(5):957-963. doi: 10.1038/s41375-023-01886-0. Epub 2023 Mar 31.
6
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.原发性骨髓纤维化和特发性血小板增多症的危险分层和治疗进展。
Curr Hematol Malig Rep. 2022 Oct;17(5):155-169. doi: 10.1007/s11899-022-00670-8. Epub 2022 Aug 6.
7
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.羟基脲耐药/不耐受的真性红细胞增多症患者接受芦可替尼或最佳可用疗法治疗后的主要临床结局的真实世界分析。
Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13.
8
Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.近年来，分子分析在为真性红细胞增多症患者的诊断和预后提供信息方面的应用进展。
Int J Mol Sci. 2021 May 10;22(9):5042. doi: 10.3390/ijms22095042.
9
New Perspectives on Polycythemia Vera: From Diagnosis to Therapy.真性红细胞增多症的新视角：从诊断到治疗。
Int J Mol Sci. 2020 Aug 13;21(16):5805. doi: 10.3390/ijms21165805.